Lv75
4740 积分 2023-01-03 加入
Oral PCSK9 Inhibitors: Can Novel Therapies Overcome Barriers to Effective LDL Cholesterol Management?
18天前
已关闭
An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo
21天前
已完结
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients
22天前
已完结
Trends in the drug target landscape for autoimmune diseases
28天前
已完结
Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy
28天前
已完结
Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain
28天前
已完结
Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering
28天前
已完结
Small Molecule Inhibitors of the PCSK9·LDLR Interaction
28天前
已完结
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists
28天前
已完结
Disrupting the PCSK9/LDLR protein–protein interaction by an imidazole-based minimalist peptidomimetic
28天前
已完结
皖公网安备34019202002308
